FDA lowers Lunesta dose due to next-day drowsiness

Prescription drugs (KSN File Photo)
Prescription drugs (KSN File Photo)

WASHINGTON (AP) — Federal health officials say the maker of Lunesta must lower the starting dose of its sleeping aid drug due to risks of morning drowsiness, which can interfere with driving ability and lead to injury.

The Food and Drug Administration is taking action based on a study that found Lunesta at recommended doses can cause problems with driving, memory and coordination up to 11 hours after first the drug is taken. Patients are often unaware that they are still drowsy.

Lunesta manufacturer Sunovion Pharmaceuticals will lower the starting dose of the tablet to 1 milligram from 2 milligrams. Patients can increase their dose, but should remember that higher doses are more likely to cause impairment the next day, according to the FDA.

Drowsiness is a side effect for all anti-insomnia drugs.

KSN.com provides commenting to allow for constructive discussion on the stories we cover. In order to comment here, you acknowledge you have read and agreed to our Terms of Service. Commenters who violate these terms, including use of vulgar language, racial slurs or consistent name calling will be banned. Please be respectful of the opinions of others. If you see an inappropriate comment, please flag it for our moderators to review.

blog comments powered by Disqus